Patient Satisfaction and Sensory Attributes of Nasal Spray Treatments for Allergic Rhinitis
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 426
- 试验地点
- 1
- 主要终点
- Overall Best-Worst Scaling Task Index Score (Treatment Satisfaction Index Score)
研究概览
简要总结
The study seeks to understand patients' satisfaction and importance of treatment attributes for Allergic Rhinitis nasal sprays from two brands (RYALTRIS® vs. DYMISTA®).
详细描述
The study seeks to understand patients' satisfaction and importance of treatment attributes for Allergic Rhinitis nasal sprays from two brands (RYALTRIS® vs. DYMISTA®).
To directly compare patient satisfaction with 2 different Allergic Rhinitis nasal sprays, an observational, cross-sectional study design with 2 independent samples was chosen. Participants will complete an online survey involving a Best-Worst scaling (BWS) task to determine satisfaction and importance index for sensory attributes.
The suggested treatment attributes are informed by a range of previous studies, including those conducted by Meltzer et al 2005 and Price et al 2020, and methodology from CaPPRe's own work in developing indices for importance and satisfaction of treatment attributes using BWS.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Allergic Rhinitis patients (moderate-to-severe Seasonal Allergic Rhinitis or Perennial Allergic Rhinitis) with or without conjunctivitis who meet the following criteria will be offered the opportunity to participate in the study:
- •Patients above 18 years old
- •Fluent in English
- •Patients initiated on RYALTRIS® or DYMISTA® nasal spray in the last 12 months and currently using treatment
- •Willing and able to provide consent to participate
排除标准
- •Have reported a loss of taste and/or smell related to COVID-19 (or other medical condition)
- •Are employed by a pharmaceutical company (to avoid conflict of interest)
- •Are employed by a vaccine company (to avoid conflict of interest)
- •Do not have access to the internet (to ensure validity of the data)
- •Are unable to read and understand English (to ensure validity of the data)
结局指标
主要结局
Overall Best-Worst Scaling Task Index Score (Treatment Satisfaction Index Score)
时间窗: Cross-sectional - through study completion, an average of 3 months
The primary study endpoint is the overall index score from the Best Worst Scaling exercise, to reflect satisfaction and importance of treatment attributes of the RYALTRIS® and DYMISTA® nasal spray. Index scores from the Best Worst Scaling exercise range from 0 to 100, with higher scores indicating higher satisfaction of treatment attributes.
次要结局
- Rescaled Scores From Best-Worst Scaling Task(Cross-sectional - through study completion, an average of 3 months)